Business

Bottom Line

Tenet is a low-margin hospital chain wrapped around a high-margin ambulatory surgery business. USPI — 533 physician-syndicated ASCs and 26 surgical hospitals — earns a ~40% segment EBITDA margin and now contributes ~44% of consolidated adjusted EBITDA on ~24% of revenue. The hospital segment, after three years of selective divestitures, is a smaller, denser, ~16% adj EBITDA margin business that prints cash but faces real 2026–2027 payer-mix headwinds.

The market most often gets two things wrong here. Underestimated: the durability of USPI's ~40% margins and Tenet's reset cost base — consolidated adj EBITDA margin is now 21.4%, up from ~12% in 2018. Overestimated: the hospital segment as a growth story; same-hospital admissions grew 1.7% in 2025 and are guided to 1–2% in 2026 against a $250M EBITDA hit from ACA exchange-subsidy expiry. Whether the stock looks cheap or expensive depends almost entirely on what multiple USPI deserves vs. SGRY.

1. How This Business Actually Works

Tenet runs two distinct profit engines that share almost nothing economically except a corporate cost stack and a managed-care contracting team. The Hospital Operations segment is a high-fixed-cost, scale-and-payer-mix business: 50 acute-care hospitals (12,494 licensed beds) plus 132 outpatient sites, primarily clustered in Texas (San Antonio, El Paso), Florida, Arizona, and Detroit. USPI is a capital-light, physician-joint-venture business: Tenet typically owns a 50–80% economic stake alongside the local physicians who drive case volume. The two segments earn their money in fundamentally different ways.

The mechanics that matter on each side:

Hospital Operations — a payer-mix and acuity machine. Revenue per adjusted admission is the single most important line. In FY2025 it grew 5.3% same-hospital while admissions grew only 1.7%. Wages, nursing, and supplies are 76% of the cost base, mostly variable to admissions, but with a wage floor that resets every year (CA healthcare-worker minimum-wage law, union contracts at 27 hospitals, 31% of staff are nurses). Profitability lives in the spread between negotiated commercial rates (3–5% annual escalators, 70% of revenue) and labor + supply cost growth — and in moving cases out of inpatient into the outpatient sites that sit inside the same segment, where margins are structurally higher. Tenet's 2024 hospital divestitures (~14 hospitals across SC, CA, AL) were not a cost cut; they were a margin-mix decision. Same-hospital salaries-wages-benefits was 46.3% of revenue in FY2025, down 140 bps from 2024.

USPI — a physician-syndication compounding machine. USPI doesn't compete for patients; it competes for physicians. The local orthopedic group, cardiologists, gastroenterologists buy in alongside USPI as JV partners and bring their cases. Once a center has the right physicians, growth comes from (a) raising acuity — moving total joints, complex spine, more cardiology into the ASC as CMS phases procedures off the inpatient-only list, (b) negotiated commercial rate increases (3–5%), (c) acquiring or building new centers (35 added in 2025 for $350M of capital), and (d) M&A. Same-facility revenue grew 7.5% in 2025, well ahead of management's "long-term 3–6%" framework, with double-digit growth in same-store joint replacements. Because Tenet doesn't own 100% of USPI's facilities, a meaningful share of segment EBITDA flows out to noncontrolling-interest holders — distributions to NCI were ~$224M in Q4 2025 alone, and 2026 guidance shows FCF after NCI of $1.6–1.83B against total FCF of $2.5–2.8B (so ~30% of FCF is non-controlling).

Conifer — a smaller third leg in transition. Conifer is Tenet's revenue cycle BPO arm with ~$25B of client patient revenue under management and a 5,600-person Manila Global Business Center. Tenet bought back the 23.8% CommonSpirit JV stake on January 1, 2026 for $540M, retired $885M of related obligations, and accelerated $1.9B of contract cash flows (after-tax NPV of the deal: ~$1.1B per management). The CommonSpirit master services agreement winds down December 31, 2026 — meaning Conifer revenue will be smaller from 2027, but margin and free-cash conversion improve materially. Treat Conifer as "small-but-clean" (~$200M EBITDA, ~25%+ margin, ~5% of consolidated EBITDA).

2. The Playing Field

Five public peers anchor the read on Tenet, and they are not all hospital chains. HCA is the scale benchmark for hospitals (3.6× Tenet's revenue, materially higher hospital margins). UHS and CYH are the cleanest reads on second-tier hospital economics — UHS as the well-managed comp, CYH as the textbook stressed-comp (negative book equity, 5.6× net debt / EBITDA). SGRY is the only listed pure-play comp for USPI — same syndicated-physician model, similar acuity migration, ~9.4× EV/EBITDA. ACHC is the behavioral-hospital comp, currently impaired and not a useful margin read for 2025.

The peer comparison reveals three things that matter. First, Tenet's consolidated margin (21.4%) is essentially equal to HCA's (21.8%) — a remarkable convergence given HCA is 3.6× larger and has historically dominated on scale. The reason is mix: USPI's 40% segment margin pulls Tenet's blend up, while HCA's hospital-heavier mix anchors its blend lower despite a stronger hospital franchise. Second, Tenet trades at a meaningful discount to both HCA (8.6×) and SGRY (9.4×) despite having both businesses inside it — a discount that only makes sense if the market is treating it primarily as a hospital chain (next to UHS at 5.3× and CYH at 5.5×). Third, Tenet's leverage (2.25× net debt / EBITDA) is now the lowest among peers ex-UHS — a structural change from 2018 when it ran at 6.2×. The deleveraging is what unlocked the buyback program (22% of shares retired since 2022).

What the best peer does better: HCA generates more cash per hospital because of denser local market shares (often #1 or #2 by share in its top markets) and a longer track record of physician alignment. SGRY has a more aggressive acquisition cadence at USPI's exact target size band but at the cost of FCF and leverage discipline. Tenet sits between them — better physician network than CYH/UHS, lower hospital concentration than HCA, more measured capital allocation than SGRY.

3. Is This Business Cyclical?

Tenet's cycle is policy-driven, not industrial. Industry-wide hospital occupancy moves a few hundred basis points across a full economic cycle; same-hospital admissions for major operators rarely deviate more than 2–3% from trend in any given year. What does move sharply is payer mix, and payer mix is set by federal and state policy (Medicaid expansion, ACA exchange subsidies, OBBBA, DSH adjustments), not by GDP.

Two recent episodes bracket the range of outcomes for Tenet's hospital segment. The 2020–2022 pandemic-and-labor cycle crushed margins industry-wide as nursing wages spiked (contract labor reached double digits as a percentage of total wages at most operators); Tenet's consolidated margin compressed from 17.8% in 2021 back to 15.3% in 2022 before recovering. The 2014–2018 ACA expansion cycle lifted commercial coverage in expansion states and reduced uninsured admissions — a tailwind that disproportionately bypassed Tenet because over half its licensed beds sit in non-expansion states (FL, SC, TN, TX). That same geographic tilt is now the source of acute downside: those four states are exactly where the expired enhanced premium tax credits are causing the sharpest exchange-enrollment declines.

The bigger policy hit comes in 2027 with OBBBA Medicaid changes (work requirements, supplemental-payment caps, eligibility checks) and the rescheduled Medicaid DSH cuts. Management has not yet quantified the OBBBA impact; CBO sees millions losing coverage by 2034. The right way to think about cycle exposure is two layers: 2026 is mostly a payer-mix problem (commercial-to-uninsured shift); 2027 is a Medicaid-funding problem (lower supplemental payments, especially in non-expansion states). USPI is largely insulated from both — its commercial/Medicare-heavy mix and ASC-only payment structure don't move with Medicaid policy. Hospital is exposed to both.

4. The Metrics That Actually Matter

Forget P/E and price-to-sales. The five metrics below are what hospital and ASC analysts actually use, and they appear every quarter for THC and its peers.

Two things to note about returns on capital. The FY2024 spike (ROIC 18.3%, ROE 57.8%) is mostly the $2.92B GAAP gain on hospital divestitures, not an operating step-change. The FY2025 reading (ROIC 11.4%, ROA 9.4%) is the cleaner picture — a real improvement from the high-single-digits of 2018–2023, but not an HCA-quality return on capital. The reason is structural: hospital businesses earn lower ROIC than ambulatory because of the goodwill burden ($11.2B at year-end, ~38% of total assets) and the heavier physical footprint. USPI alone almost certainly earns a >25% ROIC on its newer cohorts of acquired centers; the consolidated number is dragged down by hospital goodwill.

5. What Is This Business Worth?

Tenet should be valued sum-of-the-parts, because the two main segments earn different multiples for different reasons. Hospital Operations is a regulated, payer-mix-sensitive, mid-teens-margin acute-care chain that trades in the 5–7× adj EBITDA band (UHS, CYH, HCA-discount). USPI is an ASC platform with 40% margins, mid-single-digit organic growth, and an active M&A pipeline — the closest comp (SGRY) trades at 9.4× and has weaker margins, lower scale, and more leverage. Treating them as one $4.6B EBITDA stream and applying a hospital multiple — which the market often does — systematically undervalues USPI. Treating them as one $4.6B EBITDA stream and applying an ASC multiple — which sell-side bulls do — systematically overvalues the hospital piece going into 2026–2027 policy headwinds.

Binder Error: Set operations can only apply to expressions with the same number of result columns

The biggest single judgment call is what multiple USPI deserves. Three reasons it could deserve a SGRY-plus premium: scale (533 ASCs vs. SGRY's ~150), better same-facility growth (7.5% vs. SGRY ~5%), and FCF discipline (Tenet generated $2.5B in FCF in 2025 vs. SGRY ~zero). Three reasons it could deserve a discount: most of the ASC platform's optionality (inpatient-only list phase-out, joint-replacement migration) is already baked into 2025 results; ~30% of segment economics flow to physician-JV partners; and segment EBITDA is partially elevated by acquisition mix.

The biggest hospital-side judgment call is the durability of the 16% margin. Tenet got there by selling 14 lower-margin hospitals and concentrating in higher-acuity Texas/Florida markets. That mix is structurally better than 2018, but the 1.7% same-hospital admission growth is also barely above demographic baseline — meaning margin holds only as long as revenue per adjusted admission keeps growing 4–5%. That requires acuity to keep migrating up, payer-mix shifts not to swamp the gain, and labor cost growth to stay at or below 4%. All three conditions held in 2025. EPTC expiry threatens the second; OBBBA threatens the first via Medicaid funding cuts.

6. What I'd Tell a Young Analyst

Five things to internalize, in order of importance.

1. Stop reading consolidated numbers. Read segment numbers. Every important question about Tenet — what's it worth, where's the cycle, what's the moat — requires separating USPI from Hospital. The consolidated 21.4% margin is a blend that doesn't exist anywhere inside the company; in reality you have a 40%-margin business attached to a 16%-margin business. Build the model with two columns from the start.

2. The single number that resolves the bull-bear debate is USPI same-facility revenue growth. If it stays above the 6% top end of management's long-term band, the SOTP math compounds favorably and the stock is cheap. If it falls below 5% for two quarters running, the SGRY-style multiple is at risk and the stock is probably fairly valued. Track it monthly via investor-day disclosures and quarterly press releases — and watch SGRY's number as a confirming signal.

3. The hospital segment is in its "test the reset" phase. Tenet sold ~14 hospitals in 2024, kept the high-acuity, urban/suburban concentrations (San Antonio, El Paso, Florida, Detroit), and reset the cost base. 2025 worked. 2026 has a quantified $250M EBITDA headwind from EPTC expiry. 2027 has an unquantified Medicaid OBBBA hit. If management defends the 16% segment margin through both, it confirms the reset is real and the segment deserves a HCA-discount multiple, not a UHS/CYH multiple. If margins compress more than 100 bps, the reset thesis is wounded.

4. The market is most likely missing the structural change in cash flow. FCF was $321M in FY2022; $2.53B in FY2025; guided to $2.5–2.8B for 2026 with $1.6–1.83B after NCI distributions. Even at the post-NCI midpoint, that's a ~10% FCF yield on equity at $187 — high for any healthcare business with these growth dynamics. The buyback cadence (22% of shares retired since 2022 for $2.5B) implies management agrees. Don't fixate on the EPS growth rate; fixate on the per-share cash flow trajectory.

5. Three things would change the thesis materially.

• USPI same-facility growth slowing to 3–4% sustained would shift the SOTP math 15–20% lower and remove the rerate case.
• An OBBBA implementation that meaningfully caps state-directed payments before management can offset would compress hospital EBITDA by $300–500M annually and re-leverage the balance sheet.
• A site-neutral Medicare payment reform passed by Congress would benefit USPI (its ASC payments are already lower) but hurt Tenet's hospital outpatient departments — net effect probably negative for the consolidated story but mixed by segment.

Watch for the first signs of any of these in Q1–Q2 2026 commentary. Beyond that, the rest of the noise — quarterly volume jitter, weather, flu season, individual market disputes — does not change the investment case.